A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Zidovudine, Drug Administration Schedule, Stavudine, HIV Protease Inhibitors, Lamivudine, Indinavir, Dosage Forms, Nelfinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Are at least 18 years old. Have had an HIV level below 400 copies/ml for at least 3 months prior to study entry. Have a CD4 cell count of at least 50 cells/mm3. Are currently taking an anti-HIV drug regimen that includes 3TC plus d4T plus either IDV or NFV for at least 6 months prior to study entry. (Note: This must be their first anti-HIV drug regimen.) Agree to abstain from sex or use effective methods of birth control during the study. Exclusion Criteria Patients will not be eligible for this study if they: Have a history of an AIDS-defining illness or certain other medical conditions. Are allergic to any of the study drugs. Are unable to take medication by mouth for any reason. Have received certain medications. Will need to receive radiation therapy or chemotherapy (for any cancer other than Kaposi's sarcoma) during the study. Are pregnant or breast-feeding.
Sites / Locations
- AIDS Healthcare Foundation
- Palo Alto Veterans Affairs Health Care System
- Dupont Circle Physicians Group
- IDC Research Initiative
- North Broward Hosp District
- Steinhart Medical Associates
- Northwestern Univ Med School
- Saint Vincents Hosp
- St Lukes - Roosevelt Hosp Ctr
- MCP Hahnemann Univ Hosp
- Southwest Infectious Disease Association / PA
- Univ TX Galveston Med Branch